Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0915-5
Abstract: Hypercholesterolaemia is frequently observed in patients with cardiovascular diseases (CVD) and is associated with increased mortality. Statin treatment has been the standard of care for reducing low-density lipoprotein cholesterol (LDL-C) to improve cardiovascular outcomes. However,… read more here.
Keywords: monoclonal antibodies; vaccines targeting; targeting pcsk9; pcsk9 ... See more keywords
Targeting PCSK9 to reduce residual risk in ACS
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Cardiology"
DOI: 10.1038/s41569-018-0125-6
Abstract: Patients who have had an acute coronary syndrome (ACS) are at high risk of recurrent cardiovascular events, particularly patients whose LDLcholesterol (LDLC) levels remain elevated despite receiving highintensity statin therapy. The ODYSSEY OUTCOMES trial now… read more here.
Keywords: risk; pcsk9 reduce; targeting pcsk9; pcsk9 ... See more keywords
AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15425
Abstract: AZD8233 is a proprotein convertase subtilisin/kexin type 9 (PCSK9) antisense oligonucleotide under development for treatment of hypercholesterolaemia. A prespecified concentration‐QT analysis was performed based on data from a single ascending dose study that was prospectively… read more here.
Keywords: antisense oligonucleotide; targeting pcsk9; azd8233 antisense; azd8233 ... See more keywords
Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
Sign Up to like & getrecommendations! Published in 2022 at "Cardiovascular Therapeutics"
DOI: 10.1155/2022/8129513
Abstract: As dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of interest worldwide. In contrast to conventional pharmacotherapy, human monoclonal… read more here.
Keywords: targeting pcsk9; disadvantages inclisiran; small interfering; inclisiran ... See more keywords